secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0001651308-23-000061
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene reports 2022 revenue of $1.42B, R&D spend $1.64B in STAR Market filing
------------------------------------------------------------------------------

- Total revenue $1.416B (2021: $1.176B); China revenue $840M (67.1% margin), Ex-China $576M (98.3% margin).
- R&D expenses $1.641B vs $1.459B in 2021; key product spend: Zanubrutinib $127M, Tislelizumab $88.9M, Ociperlimab $106.6M.
- Production/sales/inventory: 3.28M vials produced, 2.67M sold, 1.54M in stock as of Dec 31, 2022.
- Filed PRC GAAP vs U.S. GAAP reconciliation; differences in share-based comp (accelerated vs straight-line) and lease accounting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/0001651308-23-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/bgne-20230425.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer